Should I buy or sell Belite Bio stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLTE shares. View BLTE analyst ratings or view top-rated stocks .

What is Belite Bio's stock price target for 2024?

7 brokers have issued 1 year price targets for Belite Bio's shares. Their BLTE share price targets range from $25.00 to $60.00. On average, they expect the company's share price to reach $44.83 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price. View analysts price targets for BLTE or view top-rated stocks among Wall Street analysts .

How have BLTE shares performed in 2024?

Belite Bio's stock was trading at $45.75 on January 1st, 2024. Since then, BLTE stock has decreased by 26.7% and is now trading at $33.54. View the best growth stocks for 2024 here .

Are investors shorting Belite Bio?

Belite Bio saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 39,100 shares, a drop of 34.3% from the March 15th total of 59,500 shares. Based on an average trading volume of 61,400 shares, the short-interest ratio is presently 0.6 days. View Belite Bio's Short Interest .

When is Belite Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BLTE earnings forecast .

How were Belite Bio's earnings last quarter?

Belite Bio, Inc (NASDAQ:BLTE) issued its quarterly earnings data on Monday, March, 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.11.

When did Belite Bio IPO?

Belite Bio (BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 6,000,000 shares at a price of $5.50-$6.50 per share.

How do I buy shares of Belite Bio?

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BLTE

Belite Bio (BLTE) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free BLTE Stock Alerts

$33.43

-1.17 (-3.38%)

(As of 04/19/2024 ET)

Compare

Today's Range: $32.56
▼
$35.10
50-Day Range: $32.33
▼
$48.01
52-Week Range: $11.00
▼
$48.60

Volume: 20,859 shs
Average Volume: 59,680 shs
Market Capitalization: $974.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.83

Get Belite Bio alerts:

Belite Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 33.7% Upside
$44.83 Price Target
Short Interest: Healthy
0.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.63) to ($0.80) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.29 out of 5 stars

Medical Sector

467th out of 918 stocks

Pharmaceutical Preparations Industry

211th out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
Belite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Belite Bio has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.13% of the outstanding shares of Belite Bio have been sold short.
Short Interest Ratio / Days to Cover
Belite Bio has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Belite Bio has recently decreased by 34.29%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Belite Bio does not currently pay a dividend.
Dividend Growth
Belite Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLTE.

2.6

News and Social Media Coverage

News Sentiment
Belite Bio has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Belite Bio this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for BLTE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
3 people have added Belite Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Belite Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.53% of the stock of Belite Bio is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Belite Bio are expected to decrease in the coming year, from ($0.63) to ($0.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Belite Bio is -27.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Belite Bio is -27.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Belite Bio has a P/B Ratio of 10.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Belite Bio Stock (NASDAQ:BLTE)

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

BLTE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BLTE Stock News Headlines

April 14, 2024 | americanbankingnews.com

Belite Bio (NASDAQ:BLTE) Trading Down 5.5%

April 13, 2024 | morningstar.com

Belite Bio Inc ADR

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

March 23, 2024 | finanznachrichten.de

Belite Bio, Inc: Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

March 22, 2024 | msn.com

Belite Retreats On Start Of Clinical Trial

March 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Belite Bio as Tinlarebant Shows Promising Clinical Advancements and Market Potential

March 22, 2024 | globenewswire.com

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

March 21, 2024 | markets.businessinsider.com

Buy Rating Justified for Belite Bio, Inc. ADR Amidst Promising DRAGON Trial Progress and Strong Financials

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 20, 2024 | finance.yahoo.com

Here's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn Situation

March 14, 2024 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX)

March 14, 2024 | nasdaq.com

Belite Bio is Now Oversold (BLTE)

March 14, 2024 | seekingalpha.com

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)

March 11, 2024 | globenewswire.com

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

March 11, 2024 | globenewswire.com

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 6, 2024 | globenewswire.com

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

March 4, 2024 | globenewswire.com

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

February 21, 2024 | benzinga.com

Belite Bio Stock (NASDAQ:BLTE) Insider Trades

February 7, 2024 | finance.yahoo.com

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 9, 2024 | finance.yahoo.com

Is There An Opportunity With Belite Bio, Inc's (NASDAQ:BLTE) 49% Undervaluation?

December 28, 2023 | markets.businessinsider.com

Buy Rating for Belite Bio Backed by Tinlarebant’s Promising Global Trials and Safety Profile

December 28, 2023 | benzinga.com

Belite Bio Stock (NASDAQ:BLTE) Dividends: History, Yield and Dates

November 30, 2023 | finance.yahoo.com

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

November 20, 2023 | finance.yahoo.com

Belite Bio to Participate in the BTIG Ophthalmology Day

November 17, 2023 | markets.businessinsider.com

Belite Bio’s Promising Outlook: Strong 3Q23 Results, Effective STGD1 Treatment & Solid Financial Standing Drive Buy Rating

November 16, 2023 | markets.businessinsider.com

Promising Clinical Trials and Stable Financials Bolster Buy Rating for Belite Bio, Inc. ADR

See More Headlines

Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BLTE
CUSIP: N/A
CIK: 1889109
Web: belitebio.com
Phone: 858-246-6240
Fax: N/A
Employees: 20
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $44.83
High Stock Price Target: $60.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +29.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,630,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -54.05%
Return on Assets: -50.06%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 24.76
Quick Ratio: 24.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.28 per share
Price / Book: 10.55

Miscellaneous

Outstanding Shares: 29,150,000
Free Float: 25,275,000
Market Cap: $1.01 billion
Optionable: Not Optionable
Beta: -1.62

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Yu-Hsin Lin M.B.A. (Age 45)
Ph.D., Chairman of the Board of Directors & CEO
Mr. Hao-Yuan Chuang C.F.A. (Age 39)
F.R.M., M.B.A., CFO & Director
Dr. Nathan L. Mata Ph.D. (Age 57)
Chief Scientific Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BLTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Belite Bio stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLTE shares.
View BLTE analyst ratings or view top-rated stocks.
What is Belite Bio's stock price target for 2024?: 7 brokers have issued 1 year price targets for Belite Bio's shares. Their BLTE share price targets range from $25.00 to $60.00. On average, they expect the company's share price to reach $44.83 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price.
View analysts price targets for BLTE or view top-rated stocks among Wall Street analysts.
How have BLTE shares performed in 2024?: Belite Bio's stock was trading at $45.75 on January 1st, 2024. Since then, BLTE stock has decreased by 26.7% and is now trading at $33.54.
View the best growth stocks for 2024 here.
Are investors shorting Belite Bio?: Belite Bio saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 39,100 shares, a drop of 34.3% from the March 15th total of 59,500 shares. Based on an average trading volume of 61,400 shares, the short-interest ratio is presently 0.6 days.
View Belite Bio's Short Interest.

When is Belite Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BLTE earnings forecast.
How were Belite Bio's earnings last quarter?: Belite Bio, Inc (NASDAQ:BLTE) issued its quarterly earnings data on Monday, March, 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.11.
When did Belite Bio IPO?: Belite Bio (BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 6,000,000 shares at a price of $5.50-$6.50 per share.
How do I buy shares of Belite Bio?: Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLTE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial